broad-spectrum mass spectrometry genotyping . J Mol Diagn 2011 ; 13 : 64 – 73 . 35. Kabiawu Ajise OE Feldstein JT Soslow R . Assessment of BRAF V600E mutation status by immunohistochemistry in lung and ovarian carcinomas [abstract] . Mod
Search Results
NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies
Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland
Strategies for Optimizing the Clinical Impact of Immunotherapeutic Agents Such as Sipuleucel-T in Prostate Cancer
Ravi A. Madan, Thomas Schwaab, and James L. Gulley
CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma . Gynecol Oncol 2008 ; 108 : 415 – 420 .
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, and Susan Darlow
epidemiology study . J Natl Cancer Inst 2010 ; 102 : 475 – 483 . 16. Norquist BM Harrell MI Brady MF . Inherited mutations in women with ovarian carcinoma . JAMA Oncol 2015 ; 2 : 1 – 9 . 17. Ramus SJ Song H Dicks E . Germline
What Is the Appropriate Approach to Treating Women With Incurable Cervical Cancer?
Lois Ramondetta
. Thaker PH Han LY Kamat AA . Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma . Nat Med 2006 ; 12 : 939 – 944 . 55. Wong HP Yu L Lam EK . Nicotine promotes colon tumor growth and angiogenesis
Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative
Neelima Vidula, Leif W. Ellisen, and Aditya Bardia
cancer. Presented at ESMO Congress 2019; September 27–October 1, 2019; Barcelona, Spain. 19. Oza AM , Tinker AV , Oaknin A , . Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a
Myeloid Growth Factors
Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt, and Michael Westmoreland
chemotherapy . Value Health 2008 ; 11 : 172 – 179 . 29 Numnum TM Kimball KJ Rocconi RP . Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer
Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials
Bishal Gyawali, Elvira D’Andrea, Jessica M. Franklin, and Aaron S. Kesselheim
– 1144 . 10.1200/JCO.2009.24.2024 20124182 52. Coleman RL , Oza AM , Lorusso D , . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase
The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?
Ying L. Liu and Zsofia K. Stadler
EM , Lin KK , Oza AM , Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial . Lancet Oncol 2017 ; 18 : 75 – 87 . 10.1016/S1470
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021
Featured Updates to the NCCN Guidelines
Efrat Dotan, Louise C. Walter, Ilene S. Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary Gross, Sumati Gupta, Genevieve Hollis, Joleen Hubbard, Reshma Jagsi, Nancy L. Keating, Elizabeth Kessler, Thuy Koll, Beatriz Korc-Grodzicki, June M. McKoy, Sumi Misra, Dominic Moon, Tracey O’Connor, Cynthia Owusu, Ashley Rosko, Marcia Russell, Mina Sedrak, Fareeha Siddiqui, Amy Stella, Derek L. Stirewalt, Ishwaria M. Subbiah, William P. Tew, Grant R. Williams, Liz Hollinger, Giby V. George, and Hema Sundar
. Psychopharmacol Bull 1988 ; 24 : 609 – 614 . 3074322 17. Freyer G , Geay JF , Touzet S , Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study
Myeloid Growth Factors
Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer, and Maria Ho
Kimball KJ Rocconi RP . Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer 2007 ; 17 : 1019 – 1024 . 30. Timmer-Bonte JN Adang EM Termeer
